Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults ...
Posted by Michael Wonder on 14 Jan 2018
A managed access approach to appraising new cancer drugs in England
12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...
Posted by Michael Wonder on 12 Jan 2018
Pharma collaborates to improve chances of NICE backing Duchenne drugs
11 January 2018 - A group of pharma companies and Duchenne UK are collaborating to improve the chances of new ...
Posted by Michael Wonder on 10 Jan 2018
NICE backs wider use of MSD’s Simponi
10 January 2018 - Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi ...
Posted by Michael Wonder on 08 Jan 2018
NICE to look again at Pfizer’s Besponsa after appeal
3 January 2018 - The blood cancer medicine was originally turned down on cost-effectiveness grounds. ...
Posted by Michael Wonder on 05 Jan 2018
NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’
3 January 2018 - Strimvelis, a treatment for an ultra-rare inherited immune deficiency condition that has been dubbed ‘bubble baby syndrome’ ...
Posted by Michael Wonder on 21 Dec 2017
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance
20 December 2017 - Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance. ...
Posted by Michael Wonder on 21 Dec 2017
NICE proposes restricting multiple sclerosis therapies
21 December 2017 - Novartis’ Extavia is the only beta interferon being endorsed by the NICE as a cost-effective treatment ...
Posted by Michael Wonder on 20 Dec 2017
'Drugs are too expensive for the NHS – and people are paying with their lives’
20 December 2017 - Don’t blame the NHS for denying vital medication, say members of a new activist group, Just Treatment. ...
Posted by Michael Wonder on 20 Dec 2017
NICE turns down rare skin disease implant
20 December 2017 - The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic ...
Posted by Michael Wonder on 20 Dec 2017
Takeda’s Ninlaro approved for NHS use via Cancer Drugs Fund
20 December 2017 - Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on ...
Posted by Michael Wonder on 14 Dec 2017
NICE changes its mind on Imbruvica for mantle cell lymphoma
14 December 2017 - In a reversal of a previous guidance, the UK’s NICE has issued draft guidance recommending ibrutinib ...
Posted by Michael Wonder on 12 Dec 2017
Final NHS ‘no’ for obesity pill Mysimba
12 December 2017 - An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, ...
Posted by Michael Wonder on 11 Dec 2017
NICE U-turn backs combo for kidney cancer
11 December 2017 - In a turnaround from its earlier position, the NICE is now endorsing NHS funding for Eisai’s ...
Posted by Michael Wonder on 11 Dec 2017
NHS advises GPs not to prescribe “low value” drugs
30 November 2017 - NHS England will issue guidance to GPs and commissioners to limit the prescribing of “low value” ...